[{"orgOrder":0,"company":"Bioshin","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Bioshin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Bioshin \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Bioshin \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Genpharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Genpharm","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Genpharm"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Medison Pharma"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Sixth Street","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Sixth Street","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Sixth Street"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Cove","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cove","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Cove \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Cove \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Pfizer Inc \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Biohaven Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals for Rimegepant

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide-Based Therapeutics Summit
                          Not Confirmed
                          Peptide-Based Therapeutics Summit
                          Not Confirmed

                          Details : Vydura (also known as Rimegepant) is an oral lyophilisate and is the first calcitonin gene-related peptide (CGRP) receptor antagonist migraine therapy to be accepted by the SMC.

                          Product Name : Vydura

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 05, 2023

                          Lead Product(s) : Rimegepant Sulfate

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Biohaven Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Peptide-Based Therapeutics Summit
                          Not Confirmed
                          Peptide-Based Therapeutics Summit
                          Not Confirmed

                          Details : Pfizer will acquire Biohaven, the maker of NURTEC® ODT (rimegepant sulfate). Pfizer will commercialize NURTEC® ODT, an innovative compound for the prevention and acute treatment of migraine.

                          Product Name : Nurtec ODT

                          Product Type : Other Small Molecule

                          Upfront Cash : $11,600.0 million

                          October 05, 2022

                          Lead Product(s) : Rimegepant Sulfate

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Pfizer Inc

                          Deal Size : $11,600.0 million

                          Deal Type : Acquisition

                          blank

                          03

                          Peptide-Based Therapeutics Summit
                          Not Confirmed
                          Peptide-Based Therapeutics Summit
                          Not Confirmed

                          Details : Results from long-term studies of Nurtec ODT (Rimegepant Sulfate) as a preventive and acute treatment of migraine showed more than 80% of patients achieved ≥50% reduction in moderate or severe monthly migraine days and approximately half experienced a ...

                          Product Name : Nurtec ODT

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 06, 2022

                          Lead Product(s) : Rimegepant Sulfate

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Peptide-Based Therapeutics Summit
                          Not Confirmed
                          Peptide-Based Therapeutics Summit
                          Not Confirmed

                          Details : Results demonstrate a clinically meaningful reduction in opioid use of Nurtec® ODT (rimegepant) for patient population and may be of benefit to those reliant on opioids to manage their disease, thereby alleviating potential negative consequences of opio...

                          Product Name : Nurtec ODT

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 04, 2022

                          Lead Product(s) : Rimegepant Sulfate

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Peptide-Based Therapeutics Summit
                          Not Confirmed
                          Peptide-Based Therapeutics Summit
                          Not Confirmed

                          Details : The transaction agreements, including Pfizer’s commercialization of rimegepant and zavegepant outside of the U.S., have become effective following the receipt of regulatory approvals and the satisfaction of other customary conditions and BHVN shares ha...

                          Product Name : Nurtec ODT

                          Product Type : Other Small Molecule

                          Upfront Cash : $500.0 million

                          May 01, 2022

                          Lead Product(s) : Rimegepant Sulfate

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Pfizer Inc

                          Deal Size : $1,240.0 million

                          Deal Type : Collaboration

                          blank

                          06

                          Peptide-Based Therapeutics Summit
                          Not Confirmed
                          Peptide-Based Therapeutics Summit
                          Not Confirmed

                          Details : Results from the Phase 3 study published in Lancet demonstrated that a single dose of rimegepant provided superior pain reduction and associated symptoms of migraine at two hours compared to placebo.

                          Product Name : Nurtec ODT

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 27, 2022

                          Lead Product(s) : Rimegepant Sulfate

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Pfizer Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Peptide-Based Therapeutics Summit
                          Not Confirmed
                          Peptide-Based Therapeutics Summit
                          Not Confirmed

                          Details : The acquisition brings to Pfizer a portfolio of promising calcitonin gene-related peptide (CGRP) receptor antagonists including NURTEC® ODT (rimegepant), to address needs of millions of migraine patients worldwide.

                          Product Name : Nurtec ODT

                          Product Type : Other Small Molecule

                          Upfront Cash : $11,600.0 million

                          March 10, 2022

                          Lead Product(s) : Rimegepant Sulfate

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Pfizer Inc

                          Deal Size : $11,600.0 million

                          Deal Type : Acquisition

                          blank

                          08

                          Peptide-Based Therapeutics Summit
                          Not Confirmed
                          Peptide-Based Therapeutics Summit
                          Not Confirmed

                          Details : The CHMP of the EMA adopted a positive opinion for rimegepant, a CGRP receptor antagonist and, will now be reviewed by the European Commission, whose EU trade name will be VYDURA and it will be valid in all 27 EU member states for the treatment of migrai...

                          Product Name : Nurtec ODT

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 25, 2022

                          Lead Product(s) : Rimegepant Sulfate

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Pfizer Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Peptide-Based Therapeutics Summit
                          Not Confirmed
                          Peptide-Based Therapeutics Summit
                          Not Confirmed

                          Details : Nurtec ODT, oral calcitonin-gene related peptide receptor antagonist currently approved for the acute and preventive treatment of migraine. Prior research has implicated CGRP in pathophysiology of disease and suggested therapeutic benefits of CGRP antago...

                          Product Name : Nurtec ODT

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 22, 2022

                          Lead Product(s) : Rimegepant Sulfate

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Peptide-Based Therapeutics Summit
                          Not Confirmed
                          Peptide-Based Therapeutics Summit
                          Not Confirmed

                          Details : NURTEC ODT (rimegepant) is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a quick-dissolve ODT formulation that is approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine.

                          Product Name : Nurtec ODT

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 14, 2022

                          Lead Product(s) : Rimegepant Sulfate

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Pfizer Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank